Browse the evidence

Hypoglossal nerve stimulation (HNS) produces substantial, durable improvements in AHI and symptoms with high adherence, supported by randomized trials and real-world data.

If you have moderate-to-severe sleep apnea and cannot tolerate CPAP, ask about hypoglossal nerve stimulation (HNS). It is an implanted device that stimulates the tongue to keep the airway open, offering substantial and durable relief for the right candidate.

Weight loss acts as a significant moderator for the effect of combined interventions on visceral fat area (VFA), but not for liver fat or intramuscular triglycerides (IMTG).

Losing weight helps reduce visceral fat, but it may not be enough to reduce liver or muscle fat. If you have concerns about liver or muscle fat, you may need additional strategies beyond just weight loss.

Time-restricted eating (TRE) combined with caloric restriction (CR) does not yield superior weight loss compared to caloric restriction alone in overweight and obese women.

If you are already restricting calories to lose weight, adding a strict eating window may not give you any extra weight loss benefit. You can achieve similar results with just calorie control.

A 1-month very-low-calorie ketogenic diet (VLCKD) in women with obesity causes a significant reduction in 24-hour energy expenditure (24hEE) and sleeping metabolic rate (SMR), primarily driven by the loss of lean soft tissue (LST) rather than metabolic adaptation alone.

If you follow a very-low-calorie ketogenic diet, expect your daily calorie burn to drop by about 10% after a month. This isn't just 'metabolic damage'; it's largely because you are lighter and have lost some muscle. To protect your metabolism, prioritize the protein target (1.2-1.5g/kg ideal body weight) and incorporate light resistance or walking to preserve lean tissue.

Lactobacillus sp. supplementation is safe and well-tolerated in non-comorbid obese individuals, with no significant adverse events reported.

You can take Lactobacillus probiotics with confidence regarding safety. Clinical trials show they are well-tolerated with no significant increase in side effects compared to a placebo.

Higher baseline body weight and BMI strongly predict greater absolute weight loss and fat mass reduction on a very low-calorie ketogenic diet (VLCKD), with men losing significantly more weight than women.

If you have a higher starting weight, you are likely to lose more absolute weight on a VLCKD than someone with a lower starting weight. Men also tend to lose more weight than women on this specific protocol. Use your baseline weight as a predictor of success rather than comparing yourself to others with different starting points.

Flexible time-restricted eating leads to a spontaneous reduction in total energy intake without altering macronutrient composition.

If you use an 8-hour eating window, you will likely eat fewer calories without needing to count them or change your food choices. This spontaneous reduction in energy intake is a key driver of the fat loss seen with flexible TRE.

BMI is an inadequate measure of obesity because it does not distinguish between lean muscle mass and adipose tissue, leading to misclassification of metabolic health.

Don't rely on BMI alone. If you have a normal BMI but feel unwell, ask about waist circumference and metabolic health. If you have a high BMI but are muscular, focus on metabolic markers rather than just weight.

Rapid and substantial weight reduction, such as that achieved by bariatric surgery or certain medications, may result in greater reductions in lean muscle mass compared to gradual weight reduction.

If you are undergoing rapid weight loss (e.g., surgery or strong medications), prioritize resistance training and adequate protein intake to protect your muscle mass. Monitor your body composition, not just scale weight, to ensure you are losing fat, not muscle.

Obesity severity (Class I, II, III) is directly correlated with increased direct medical costs, with Class III obesity costing up to 3.3 times more than normal weight individuals.

Higher obesity classes (II and III) are associated with significantly higher medical costs (up to 3.3x normal weight). This highlights the economic urgency of addressing obesity, especially in higher severity classes, through early intervention.

Bariatric surgery significantly reduces the incidence of obesity-associated cancers and cancer-specific mortality compared to non-surgical controls.

For individuals with morbid obesity, bariatric surgery is a highly effective intervention for reducing cancer risk. Discuss surgical options with a specialist if lifestyle changes are insufficient.

High cardiorespiratory fitness (CRF) mitigates or eliminates the 'obesity paradox' in heart failure, meaning overweight patients with high CRF do not have better survival than normal-weight patients with low CRF.

For heart failure patients, being overweight is not inherently protective if you are unfit. High cardiorespiratory fitness (CRF) is the key determinant of survival. Focus on improving your fitness through exercise (like the 6-minute walk test or CPX) rather than just focusing on BMI, as high fitness eliminates the 'obesity paradox' survival advantage.

GLP-1 receptor agonist therapy induces predictable reductions in fat-free mass (approximately 30-40% of total weight loss) due to sustained negative energy balance, not direct catabolic effects.

Expect that about a third of your weight loss on GLP-1s will be muscle/fluid, not just fat. This is normal physiology, not a side effect. To mitigate this, prioritize protein intake and resistance training, especially if you have low testosterone.

Higher body mass index (BMI) causes structural remodeling of the right ventricle, specifically increasing end-diastolic and end-systolic volumes, independent of left ventricular measures.

Maintaining a healthy BMI is crucial for protecting the structure of your right ventricle. This study shows that higher body weight is causally linked to larger heart volumes, which can lead to dysfunction over time. Weight management strategies, including diet and exercise, can help prevent this structural remodeling.

Tirzepatide improves metabolic and inflammatory markers in alcohol-consuming rodents, including reducing body weight, white adipose tissue, hepatic triglycerides, and pro-inflammatory cytokines.

Tirzepatide improves metabolic health and reduces inflammation in alcohol-consuming rodents, potentially addressing comorbidities of AUD.

Higher BMI (Class 2+ obesity, ≥35 kg/m2) is consistently associated with increased odds of mobility, severe mobility, and IADL disability in older adults with type 2 diabetes, regardless of intervention group.

Maintaining a BMI below 35 kg/m2 is crucial for preserving mobility and independence in older adults with type 2 diabetes. While moderate weight loss might not be the primary goal for everyone, avoiding Class 2+ obesity (BMI ≥35) is strongly associated with lower risks of severe mobility and instrumental activities of daily living (IADL) disability.

By 2025, GLP-1RAs are anticipated to receive FDA approval for new indications including chronic kidney disease and heart failure.

Healthcare providers should stay informed about upcoming indications for GLP-1RAs to optimize treatment options.

The use of safe and effective weight-loss medications may influence referral patterns for MBS in the future.

Practitioners should consider the evolving landscape of obesity treatment when referring patients for MBS.

Bariatric surgery significantly reduces the risk of developing heart failure and improves mortality in patients with existing heart failure and obesity.

For severe obesity, bariatric surgery is a highly effective treatment that can prevent heart failure and significantly improve survival in those who already have it. It is safe and can even be used as a bridge to heart transplantation in severe cases. Consult with a bariatric surgeon and cardiologist to see if you are a candidate.

The reduction in schizophrenia risk associated with GLP-1 receptor agonists is mediated by body mass index (BMI) rather than glycemic control.

The mental health benefits of GLP-1 drugs for schizophrenia risk appear to come from weight loss, not from lowering blood sugar. This means that interventions focusing on weight management (whether through GLP-1 drugs or other means) may be the key to reducing this specific psychiatric risk. It highlights the importance of addressing obesity in mental health prevention strategies.

Overweight status (BMI 25-<30) is not associated with increased risk for most cardiovascular outcomes and may have a neutral or slightly protective effect on all-cause mortality compared to normal weight.

Being overweight is not as strongly linked to heart disease or death as obesity. While weight management is still beneficial, the urgency is lower for overweight individuals compared to those with obesity. Focus on overall health metrics rather than just weight.

Chronic nutrient overload and sedentary behavior lead to 'oxidative distress' (excessive ROS), which causes insulin resistance in skeletal muscle by activating stress kinases (JNK, p38 MAPK) that inhibit insulin signaling.

Insulin resistance in skeletal muscle often starts with chronic nutrient overload, not just sugar. When you consistently consume more energy than you burn, it creates 'oxidative distress' that blocks insulin signals. Managing total energy balance and activity levels is critical to preventing this specific type of metabolic damage.

SGLT2 inhibitors improve mitochondrial function and reduce oxidative stress, contributing to their cardioprotective and renoprotective effects.

SGLT2 inhibitors may help your cells produce energy more efficiently and reduce cellular stress, which protects your heart and kidneys. This is part of why these drugs work beyond just lowering blood sugar.

Bone Mineral Content (BMC) continues to decline during the weight regain phase (6-12 months) even when total body weight and fat mass are increasing.

If you lose a significant amount of weight (5% or more), your bone density may drop. This drop can continue even if you regain some of the weight later. To protect your bones, consider baseline bone density assessments if you are at risk (e.g., postmenopausal women) and ensure adequate calcium and vitamin D intake alongside resistance training.